Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | MET | P08581 | 6/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28218196 | 0.98 | NPC1 (0.55) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL5546704 | 0.85 | DAO (0.54) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL3821378 | 0.85 | ALDH1A1 (0.53) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL5540682 | 0.82 | DAO (0.51) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL5535997 | 0.81 | DAO (0.50) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL28152082 | 0.81 | DAO (0.50) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL19338490 | 0.81 | NPC1 (0.57) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL4375850 | 0.81 | NPC1 (0.57) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL21169605 | 0.81 | NPC1 (0.57) | NPC1POLBRAB9AALDH1A1MAPT | |
| SCHEMBL507149 | 0.81 | ALDH1A1 (0.58) | NPC1POLBRAB9AALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| WO-2023023513-A9 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | UNIVERSITY OF MASSACHUSETTS (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2023023513-A1 | STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE | UNIVERSITY OF MASSACHUSETTS (US) | 2023-02-23 | — | — | WO | claimed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| WO-2024101402-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | 中外製薬株式会社 | 2024-05-16 | — | — | WO | disclosed |
| WO-2024101386-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | 中外製薬株式会社 | 2024-05-16 | — | — | WO | disclosed |
| WO-2024096023-A1 | METHOD FOR REMOVING DIBENZOFULVENE OR DIBENZOFULVENE DERIVATIVE | 中外製薬株式会社 | 2024-05-10 | — | — | WO | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024085235-A1 | METHOD FOR PRODUCING CYCLIC PEPTIDE CRYSTALS | 中外製薬株式会社 | 2024-04-25 | — | — | WO | disclosed |
| WO-2024080333-A1 | METHOD FOR PRODUCING N-SUBSTITUTED AMINO ACID RESIDUE-CONTAINING CYCLIC PEPTIDE COMPOUND | 中外製薬株式会社 | 2024-04-18 | — | — | WO | disclosed |
| WO-2024080308-A1 | COMPOSITION CONTAINING PEPTIDE, SURFACTANT, AND POLYMER | 中外製薬株式会社 | 2024-04-18 | — | — | WO | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1585775-A | 6-O-acyl ketolide derivatives of erythromycine useful as antibacterials | ORTHO MCNEIL PHARM INC (US) | 2005-02-23 | — | — | CN | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| CN-1538956-A | Spiro compounds | ������ҩ��ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| EP-1453847-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003050132-A1 | 6-O-ACYL KETOLIDE DERIVATIVES OF ERYTHROMYCINE USEFUL AS ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | NPC1 1416/4885POLB 3892/4885RAB9A 2154/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NPC1 2404/4885POLB 1637/4885RAB9A 2824/4885 |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | NPC1 4316/4885POLB 2268/4885RAB9A 130/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | NPC1 2474/4885POLB 4081/4885RAB9A 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.